Sucrase-Isomaltase Deficiency, Irritable Bowel Syndrome
Conditions
Keywords
gastrointestinal symptoms, glucose
Brief summary
The investigators know that many patients with irritable bowel syndrome (IBS) have functional variants of genes coding for sucrase-isomaltase enzymes. The investigators will now examine whether these functional variants are associated with defect degradation of sucrose and associated gastrointestinal symptoms
Detailed description
The investigators have in a previous study included IBS patients for treatment with a starch- and sucrose reduced diet (SSRD). The investigators found a great improvement of symptoms. The investigators gene-tested those patients, and now have the full identification of all functional variants encoding sucrase-isomaltase enzymes. The investigators will invite patients from this previous study with normal genes and functional variants of genes. The patients will come fasting over night to the department of clinical research. The participants will ingest 75 g sugar dissolved in 0.8 dl water and flavored with lemon, to ingest during 5 minutes. After that, glucose will determined repeatedly up to 2 hours afterwards. At the same time, the participants have to assess their gastrointestinal sympotms on visual analogue scales (VAS). The investigators will compare the raise in b-glucose and symptoms between the groups of patients, divided into gene expression.
Interventions
DIETARY_SUPPLEMENTSugar
75 g sugar dissolved in 0.8 dl water and flavored with lemon. Ingested during 5 minutes
Sponsors
Region Skane
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Patients with normal genes and with functional variants of sucrase-isomaltase genes
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Participants of our previous clinical trial with SSRD diet (NCT03306381)
Exclusion criteria
* Difficulties in taking blood samples
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes from baseline of blood glucose levels | From distribution repeatedly up to 2 hours | Measurement of glucose levels in blood drawn from an intravenous needle and analyzed at the Department of Clinical Chemostry |
| Change from baseline of gastrointestinal symptoms | From baseline and up to 2 hours, at the same time points as blood glucose is measured | Measurment of gastrointestinal symptoms on a visual analog scale measuring symptoms, range 0-100 mm, repeatedly at the same time points as blood glucose is measured. The higher scores, the worse symptoms. |
Countries
Sweden
Outcome results
None listed